Skip to Content
Merck
All Photos(1)

Key Documents

15236

Sigma-Aldrich

N,O-Bis(trimethylsilyl)carbamate

≥98.0% (T)

Synonym(s):

BSC, Trimethylsilyl N-(trimethylsilyl)carbamate

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
(CH3)3SiNHCO2Si(CH3)3
CAS Number:
Molecular Weight:
205.40
Beilstein:
2043399
EC Number:
MDL number:
UNSPSC Code:
12352100
PubChem Substance ID:
NACRES:
NA.22

Quality Level

Assay

≥98.0% (T)

form

solid

mp

77-83 °C

functional group

amine

SMILES string

C[Si](C)(C)NC(=O)O[Si](C)(C)C

InChI

1S/C7H19NO2Si2/c1-11(2,3)8-7(9)10-12(4,5)6/h1-6H3,(H,8,9)

InChI key

DGIJAZGPLFOQJE-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Other Notes

Extremely suitable reagent for the silylation of alcohols, phenols and carboxylic acids. The only by-products are CO2 and NH3; Silyloxycarbonylation of amines; Acylisocyanates from carboxylic acid chlorides

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Gregor Vlacic et al.
Cells, 8(9) (2019-09-19)
Malignant pleural mesothelioma (MPM) is a devastating malignancy with limited therapeutic options. Fibroblast growth factor receptors (FGFR) and their ligands were shown to contribute to MPM aggressiveness and it was suggested that subgroups of MPM patients could benefit from FGFR-targeted
Ronak Saluja et al.
Journal of oncology practice, 14(5), e280-e294 (2018-03-31)
The purpose of this study was to determine if clinical benefits of novel anticancer drugs, measured by the ASCO Value Framework and European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale, have increased over time in parallel with
Stefania De Lorenzo et al.
Scientific reports, 8(1), 9997-9997 (2018-07-04)
There is a relative lack of evidence about systemic treatments in patients with hepatocellular carcinoma (HCC) and moderate liver dysfunction (Child-Pugh B). In this multicenter study we retrospectively analyzed data from Child-Pugh B-HCC patients naïve to systemic therapies, treated with
Yi-Long Wu et al.
BMC cancer, 11, 430-430 (2011-10-11)
Previous research suggests the therapeutic cancer vaccine L-BLP25 potentially provides a survival benefit in patients with locally advanced unresectable stage III non-small cell lung carcinoma (NSCLC). These promising findings prompted the phase III study, INSPIRE, in patients of East-Asian ethnicity.

Articles

Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs

Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs

Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs

Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service